Tretazicar

Overview

Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Quinone Reductase | Products > Signaling Pathways > DNA Alkylator/Crosslinker

Product Information

• Catalog No.: HY-13543
• CAS No.: 21919-05-1
• Molecular Formula: C9H8N4O5
• Molecular Weight: 252.18
• Purity: 99.65%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (8.25 mM); Clear solution
• Availability: In-stock

Source

Original product source